Floatz logo

Tisagenlecleucel

Follicular Lymphoma

Novartis PharmaceuticalsCell therapyPhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
65/ 100

Competitive context

127 Active assets in the Follicular Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Merck Sharp & Dohme LLC
Phase 4BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Sun Yat-sen University
Phase 4BB
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 4BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 4BB
Bendamustine
Merck Sharp & Dohme LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →